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Pulmonary hypertension (PH) is currently deﬁned based on invasive
measurements: a resting pulmonary artery pressure  25 mm Hg. For
pulmonary arterial hypertension, a pulmonary arterial wedge pressure
 15 mm Hg and pulmonary vascular resistance > 3 Wood units are
also required. Thus, right heart catheterization is inevitable at present.
However, the diagnosis, follow-up, and management of PH by nonin-
vasive techniques is progressing. Signiﬁcant advances have been
achieved in the imaging of pulmonary vascular disease and the right
ventricle. We review the current sensitivities and speciﬁcities of
noninvasive imaging of PH and discuss its role and future potential to
replace hemodynamics as the primary approach to screening, diag-
nosing, and following/managing PH.Received for publication January 12, 2015. Accepted January 23, 2015.
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L’hypertension pulmonaire (HP) est actuellement deﬁnie selon des
methodes effractives de mesure : une pression arterielle pulmonaire
 25 mm Hg au repos. Pour deﬁnir l’hypertension arterielle pulmon-
aire, une pression arterielle pulmonaire d’occlusion  15 mm Hg et
une resistance vasculaire pulmonaire > 3 unites Wood sont
egalement requises. Par consequent, le catheterisme cardiaque droit
est inevitable pour le moment. Malgre cela, le diagnostic, le suivi et la
prise en charge de l’HP par des techniques non effractives evoluent.
L’imagerie des maladies vasculaires pulmonaires et du ventricule droit
a connu d’importants progrès. Nous passons en revue la sensibilite et
la speciﬁcite actuelles de l’imagerie non effractive de l’HP, et discutons
de ses rôles et de son potentiel futur de remplacement de l’hemody-
namique comme principale approche en matière de depistage, de
diagnostic, de prise en charge/suivi de l’HP.Pulmonary arterial hypertension (PAH) is an orphan condi-
tion with high morbidity and mortality. Despite increased
awareness of pulmonary hypertension (PH), data indicate that
the majority of patients are still diagnosed in late stages of the
disease. A higher World Health Organization functional class
is associated with poorer median survival, illustrating the
importance of early diagnosis. In this article, we were asked to
defend the value of noninvasive imaging in the diagnosis and
follow-up of PH. Although we agree that at this point, inva-
sive assessment remains essential, in the long term it is hoped
that noninvasive methods will eliminate the need for invasive
assessment. Our original mandate was to discuss PAH; how-
ever, because this is a rare condition with relatively littleinformation available, we have broadened our approach to
include PH in general.Limitations of Invasive Assessment
Invasive hemodynamic assessment by right heart
catheterization is relatively safe but has technical
limitations
At the Nice 5th World Symposium on PH, right heart
catheterization (RHC) was conﬁrmed as essential for the
diagnostic workup of PH to assess the severity of the disease and
to perform a vasoreactivity test.1-3 However, RHC is associated
with rare, albeit serious, procedure-related complications,
including death. In an analysis of 7218 RHC procedures per-
formed in experienced PH centres, 76 serious adverse events,
including 4 fatalities, were observed. Themost common serious
adverse events were supraventricular and ventricular tachy-
cardia, vagal reactions, and systemic hypotension.4 Although
RHC is relatively safe, reports of complications do appear, even
in expert centres.5
Data acquisition during RHC requires resting supine
patients. There is no standard operating procedure fordian Cardiovascular Society. This is an open access article under the CC BY
Table 1. Noninvasive imaging to screen for PH
First author Technique Number of patients Study population/cause Functional parameter/variable
Screening for PH
Sensitivity
(95% CI), %
Speciﬁcity
(95% CI), %
Denton et al.24 TTE 33 CTD (SSc) sPAP 90 75
Parent et al.25 TTE 385 Sickle cell disease Tricuspid regurgitation jet velocity 100 80
Rajaram et al.26 TTE 81 CTD Tricuspid gradient 86 82
Wang et al.27 TTE 123 CHD sPAP 89 84
Kuriyama et al.28 CT 23 Suspected PH MPAD 69 100
Perez-Enguix et al.29 CT 71 Candidates for LTX MPAD 66 86
Rajaram et al.26 CT 81 CTD Ventricular mass index 85 82
Stevens et al.30 MRI 100 Suspected PH PVR 92.5 85.2
Rajaram et al.26 MRI 81 CTD RV mass index 85 82
CHD, congenital heart disease; CT, computed tomography; CTD, connective tissue disease; LTX, lung transplantation; MPAD, main pulmonary artery
diameter; MRI, magnetic resonance imaging; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RV, right ventricular; sPAP, systolic pulmonary
artery pressure; SSc, systemic sclerosis/scleroderma; TTE, transthoracic echocardiography.
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posture or with physical activity using RHC. In addition,
hemodynamic measurements acquired by RHC are subject to
intraindividual spontaneous variability and represent only a
hemodynamic snapshot.1,6
Routine RHC relies on the use of ﬂuid-ﬁlled catheters,
which have an insufﬁcient frequency response.7 Standard Swan-
Ganz catheter manometry systems used in clinical practice have
a frequency response of 12 Hz, whereas a minimum of 50 Hz
would be required for the assessment of instantaneous pressure
signals.7 Fluid-ﬁlled catheters require fast ﬂushes to remove air
bubbles in the monitoring system, which account for most
of the variability compared with the true gold-standard high-
ﬁdelity micromanometer-tipped catheters.7 In contrast to high-
ﬁdelity micromanometer-tipped catheter systems, ﬂuid-ﬁlled
catheter transducers have to be positioned at a “zero reference
level,”which is most accurately obtained at midthoracic level or
at one third of the thoracic diameter below the anterior thorax
surface.8 A deviation of 1 cm of the transducer from zero level
affects pressures by 0.78 mm Hg, thus leading to signiﬁcantly
different results if 2 different zero reference levels are used in a
single patient.8
Currently used invasive cardiac output measurements
estimate but do not measure true cardiac output
The gold standard for the assessment of cardiac output (CO)
is the direct Fick method in which CO equals O2 consumption
divided by the difference between arterial and venous O2
content. Although O2 consumption can be measured accu-
rately, that measurement is cumbersome, and many labora-
tories use standard tables for an assumed value instead of direct
measurements. Such estimation may cause an error of as much
as 40% in the assessment of CO.9 Most laboratories now use
thermodilution based on an indicator dilution methodology to
measure CO.10 When compared with the direct Fick method,
thermodilution measurements show little bias, with a mean
difference of 0.1 L/min and a conﬁdence interval of 0.2 L/min,
corresponding to excellent accuracy even in the presence of
tricuspid regurgitation, but limits of agreement are  1 L/min,
corresponding to moderate precision.11
Need for an integrated diagnostic approach
Clinically signiﬁcant information is gained from RHC that
helps guide decisions. A restrictive use of RHCmay delay a timelydiagnosis and treatment.6 Still, the simple distinction between pre-
and postcapillary PH is a task that often cannot even be achieved
by invasive RHC. In particular, heart failure with preserved ejec-
tion fraction is commonly misdiagnosed as precapillary PH.12-14
Unresolved issues are the assessment of precatheterization ﬂuid
status, standardization of ﬂuid loading,3,15,16 and mean pulmo-
nary arterial wedge pressure measurementsdend-expiratory or as
pressure-time integral.16,17 The interpretation of invasive hemo-
dynamics is meaningless outside the context of the clinical picture,
in particular echocardiography.1,3 To manage the growing num-
ber of PH cases resulting from left heart disease (group 2 PH) and
caused by lung disease/hypoxia (group 3 PH) in the general
population, successful noninvasive diagnostic algorithms
combining multiple parameters have been developed to avoid
unnecessary RHC.1,18Present Value of Noninvasive Techniques
Advanced imaging tools are useful for screening
Transthoracic Doppler echocardiography is the predomi-
nant screening modality in early stages of diagnosis to assess
right ventricular (RV) structure and function, including the
degree of ventricular remodelling as well as the derivation of
RV systolic and diastolic pressures and analysis of contraction
timing,19-23 thus providing a reliable method for the early
detection of PH, with a particularly high sensitivity and
speciﬁcity in systemic sclerosis (Table 1). Recently, software
programs for 2-dimensional (2D) strain analysis by speckle
tracking have been applied to evaluate the right ventricle.31
Furthermore, signiﬁcant progress has been made in the use
of knowledge-based reconstruction of 3D RV structure and
function from 2D images.32 Studies have suggested that 3D
echocardiographic imaging of the right ventricle is feasible,
and its results compare well with magnetic resonance imaging
(MRI).33,34
Theoretically, imaging of the pulmonary vasculature
should be more sensitive to screening because this is where
disease starts; yet, the available methods do not appear to have
reached adequate sensitivity and speciﬁcity for that purpose.35
Advanced imaging tools are useful for diagnosis
Any patient with unexplained PH should be evaluated for
chronic thromboembolic PH (CTEPH).Diagnostic algorithms
Table 2. Noninvasive imaging to diagnose PH
First author Technique No. of patients Study population/cause Functional parameter/variable
Diagnosing PAH
Sensitivity
(95% CI), %
Speciﬁcity
(95% CI), %
Isobe et al.46 TTE 77 Controls vs suspected PH RV acceleration time 93 97
Tei et al.47 TTE 63 Controls vs iPAH Tei index e e
Saba et al.48 TTE 26 Suspected PH sPAP 89 57
Hsu et al.49 TTE 49 CTD (SSc) sPAP 58 96
Dahiya et al.50 TTE 26 Suspected PH Corrected PVR
Echocardiographic PVR
91
93
90
91
D’Alto et al.51 TTE 161 Suspected PH Left atrial pressure
Cardiac output
mPAP
PVR
85
e
e
e
e
e
e
e
Gladue et al.52 TTE 248 CTD (SSc) sPAP 94* 73*
Tan et al.53 CT 45 Suspected PH MPAD 87 89
Chan et al.54 CT 101 Suspected PH MPAD
MPAD/AA ratio
MPAD/DA ratio
Right descending PA diameter
RV/LV lumen ratio
RV/LV wall ratio
RV free wall
True left descending PA diameter
True right descending PA diameter
77
74
77
83
86
79
81
79
83
90
92
90
85
86
84
92
92
88
Corson et al.55 CT 305 Suspected PH Right PA diameter
MPAD
89 (85-94)
89 (84-93)
82 (74-89)
83 (76-90)
Helmberger et al.56 CT 24 Controls vs PH Pulmonary vessel tortuosity 83 83
Pienn et al.45 CT 21 Controls vs PAH Propagation contrast medium speed 100 (77-100) 100 (48-100)
Bouchard et al.57 MRI 27 Controls vs PAH Left descending PA/DA
MPAD
MPAD/AA
RV wall thickness
Septal wall thickness
e e
Saba et al.48 MRI 26 Suspected PH Ventricular mass index 84 71
Sanz et al.58 MRI 59 Controls vs PAH Average blood velocity
Minimum PA area
93 (81-98)
93 (81-98)
82 (57-96)
88 (64-98)
Sanz et al.58 MRI 72 PH Delayed contrast enhancement e e
Hsu et al.49 MRI 49 CTD (SSc) MPAD 68 71
Nogami et al.59 MRI 20 Suspected PH sPAP
Stroke volume
e
e
e
e
Shehata et al.60 MRI 48 Controls vs PAH RV longitudinal strain
RV circumferential strain
RV tangential strain
e
e
e
e
e
e
Swift et al.61 MRI 64 Suspected PH sPAP
PVR
87 90
AA, ascending aorta; CT, computed tomography; DA, descending aorta; CTD, connective tissue disease; iPAH, idiopathic pulmonary arterial hypertension; LV,
left ventricular; MPAD, main PA diameter; mPAP, mean PA pressure; MRI, magnetic resonance imaging; PA, pulmonary artery; PAH, pulmonary arterial hy-
pertension; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RV, right ventricular; sPAP, systolic PA pressure; SSc, systemic sclerosis/scleroderma;
TTE, transthoracic echocardiography.
* In combination with pulmonary function tests.
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Advanced Imaging Tools for Managing PAHfor PH include ventilation/perfusion (V/Q) scintigraphy,1,36-40
multidetector computed tomography (CT), and cardiac MRI
(cMRI).41 Although a mosaic pattern is common in CTEPH, it
occurs in up to 12% of patients with PAH.42 MRI of the pul-
monary vasculature is still considered inferior to CT but may be
preferred according to local practice.43 Recent advancesdsuch
as dual-energy CT,44 cone-beam CT, electrocardiographic
gated 320-row area detector CT, and lung perfusionMRIdare
about to change paradigms in pulmonary vascular imaging. In a
pilot study, dynamic contrast-enhanced CT was used to
distinguish between patients with and those without PAH by
contrast material bolus propagation time and speed in the
pulmonary arteries.45 Time differences between bolus peaks
correlated with mean pulmonary artery pressures, and
discrimination could be achieved with a sensitivity of 100% andspeciﬁcity of 100% in patients without PH and a sensitivity of
93% and speciﬁcity of 80% in patients with PAH, respectively
(Table 2).45
Suspicion should be high when the patient presents with a
history of previous venous thromboembolism (VTE). Although
formal screening cannot be recommended, CTEPH should be
ruled out in any survivor of a pulmonary embolism with
persistent dyspnea and> 15% perfusion defects 6 months after
the acute VTE after at least 3 months of effective oral anti-
coagulation.40 V/Q planar images in at least 6 views combined
with single-photon emission CT remains the preferred initial
diagnostic test for CTEPH. CT pulmonary angiography
(CTPA) has a sensitivity of detecting CTEPH of 51%,
compared with a > 96% sensitivity of V/Q scanning.62 A
normal V/Q, but not a normal CTPA, can exclude CTEPH,
Figure 1. Imaging in a 24-year-old woman with a history of progressive shortness of breath on exertion, deep vein thrombosis, and recent he-
moptysis. (A) Transthoracic echocardiographic 4-chamber view with severe right ventricular dilatation. (B) Technetium-99melabeled aerosol
ventilation and (C) perfusion images show nonmatched perfusion defects of right lower lobe and almost the entire left lung.
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Volume 31 2015although scans tend to normalize as disease progresses.63
CTEPH may be the single PH subset in which advanced im-
aging and not RHC may be the primary approach to diagnosis,
follow-up, andmanagement. In the example shown in Figure 1,
the correct diagnosis of CTEPH was made after an echocar-
diogram and a V/Q scan had been obtained. A CTEPH diag-
nosis was later conﬁrmed byRHC and pulmonary angiography.
Advanced imaging tools are useful for follow-up and
management
An important more recent ﬁnding is that although PH is a
pulmonary vascular disorder, structural and functional assess-
ments of the right ventricle play a central role in both diagnosis
and serial follow-up of patients with PAH.23 Therefore, it is
reasonable that current guidelines suggest an integrated diag-
nostic algorithm in which noninvasive modalities are targeted to
RV function and can be serially assessed to detect changes
(Table 3); such an algorithm will play an ever more important
role in the near future.1 For example, the use of 3D speckle
tracking to assess area strain, radial strain, longitudinal strain, andcircumferential strain correlates with clinical outcomes, with area
strain and circumferential strain correlating bestwithRV ejection
fraction.70 Stroke volume and RV ejection fraction measured by
cMRI are themost commonly used parameters to evaluate global
systolic RV function and to assess response to therapy.74,75,79
However, these parameters are highly dependent on preload
and afterload and do not reﬂect RV contractility.80 RV end-
systolic elastance (Ees) is accepted as a load-independent mea-
sure of intrinsic myocardial contractility. Ees is usually derived
from pressure-volume loops by invasive conductance catheteri-
zation. Using this method, arterial elastance (Ea) as a measure of
RV afterload can also be determined. RV-toepulmonary
vascular (RV-PV) coupling, the adaptation of the right ventricle
to its afterload, can be calculated by Ees divided by Ea (Ees/Ea
ratio). However, this method requires the assessment of
pressure-volume loops during preload reduction by temporary
balloon occlusion of the inferior vena cava, thus making it very
invasive and potentially dangerous. As an alternative, Ees/Ea can
also be determined by combining measurements from standard
RHC and MRI. Studies in healthy individuals and patients with
PH have shown good agreement of MRI conductance
Table 3. Noninvasive imaging to follow-up/detect change in PH
First author Technique
No. of
patients Study population/cause
Functional
parameter/variable
Detecting change in PAH/CTEPH/PH
Sensitivity
(95% CI), %
Speciﬁcity
(95% CI), %
Chow et al.64 TTE 28 Operable CTEPH
before vs after PEA
Acceleration time
Tricuspid regurgitation jet velocity
e
e
e
e
Eysmann et al.65 TTE 26 iPAH Pericardial effusion
Tricuspid early ﬂow deceleration
Pulmonary acceleration time
e
e
e
e
e
e
Tei et al.47 TTE 63 Controls vs iPAH Tei index e e
Yeo et al.66 TTE 53 iPAH Tei index e e
Raymond et al.19 TTE 81 iPAH Right atrial area index
Diastolic eccentricity index
Pericardial effusion
e
e
e
e
e
e
Forﬁa et al.67 TTE 63 PAH TAPSE e e
Dahiya et al.50 TTE 10 PAH Corrected PVR
Echocardiographic PVR
e
e
e
e
Fine et al.68 TTE 575 PH RV longitudinal strain
TAPSE
79
61
e
e
Grünig et al.69 TTE 124 PAH/CTEPH sPAP; response to exercise 77 53
Smith et al.70 TTE 97 PH RV ejection fraction
TAPSE
RV area strain
RV circumferential strain
RV longitudinal strain
RV radial strain
65
70
80
65
90
75
59
59
54
73
52
51
Courand et al.71 TTE 100 PAH RV ejection fraction e e
Moledina et al.35 CT 31 Pediatric PAH Fractal dimension e e
Zylkowska et al.72 CT 264 PAH/CTEPH MPAD 95 39
van Wolferen et al.73 MRI 64 PAH RV ejection fraction
RV end-diastolic volume index
LV end-diastolic volume index
Stroke volume index
e
e
e
e
e
e
e
e
van de Veerdonk et al.74 MRI 76 PAH RV ejection fraction 82 75
Freed et al.75 MRI 58 PH RV ejection fraction
RVIP-LGE
100 e
Ley et al.76 MRI 20 PAH/CTEPH Cardiac output e e
Pandya et al.77 MRI 50 Pediatric PAH (CHD) Septal curvature 83 (36-99) 91 (77-97)
CT, computed tomography; CHD, congenital heart disease; CTEPH, chronic thromboembolic pulmonary hypertension; iPAH, idiopathic pulmonary arterial
hypertension; LGE, late gadolinium enhancement; LV, left ventricular; MPAD, mean PA diameter; MRI, magnetic resonance imaging; PA, pulmonary artery; PAH,
pulmonary arterial hypertension; PEA, pulmonary thromboendarterectomy; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RV, right ven-
tricular; RVIP, RV insertion point; sPAP, systolic PA pressure; SV/ESV, stroke volume/end-systolic volume ratio; TAPSE, tricuspid annular plane excursion; TTE,
transthoracic Doppler echocardiography.
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Advanced Imaging Tools for Managing PAHcatheterization data.81,82 The ratio of stroke volumeetoeend-
systolic volume (SV/ESV) that can be derived completely non-
invasively from cMRI was found to correlate well with RV-PV
coupling and to be a strong predictor of prognosis.78
Conclusions
Because of the intrinsic properties of invasive diagnostics, the
desire of patients, patient advocates, and physicians is that
advanced imaging tools rather than hemodynamics will even-
tually become the primary approach to diagnosing, following,
andmanaging PH. The values of sensitivities and speciﬁcities of
available methods shown in Tables 1-3 allow for the selection of
the best noninvasive tests for screening, diagnosis, and follow-
up in PH, according to testing priorities. Although noninva-
sive assessment cannot currently replace RHC, it has become an
essential part of the management paradigm for PH, and hope-
fully with further development will 1 day make RHC a his-
torical curiosity.
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